medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (2)

Epidemiology of sickle cell disease in Latin-American and Caribbean Countries

Svarch E, Machín GSA

Language: Spanish
References: 54
Page: 1-14
PDF size: 338.56 Kb.


ABSTRACT

Introduction: Sickle cell disease is the most common congenital hemolytic anemia and is a worldwide health concern. The disease originated in Sub-Saharan Africa, the Mediterranean basin, and some regions of the Middle East and India. Slave trade between 1650 and 1830 and human migratory dynamics have affected the distribution of the disease.
Objective: To describe the epidemiology and current status of sickle cell disease in Latin America.
Methods: A literature review was carried out through the PubMed and SciElo websites, as well as the Google Scholar search engine, of articles published in the last ten years. The search terms were drepanocitosis [sickle cell disease], epidemiología [epidemiology], frecuencia [frequency], screening prenatal y postnatal [pre- and post-natal screening], Latinoamérica [Latin America]. An analysis and summary of the revised bibliography was made.
Information analysis and synthesis: Hemoglobinopathies, particularly sickle cell disease, are becoming increasingly important globally, due to their high frequency of appearance. Early diagnosis, the use of prophylactic penicillin in the first years of life, and better understanding of the genetic and non-genetic factors that influence phenotypic severity are still limited. One of the most critical problems in management and control of this disease is its extraordinary phenotypic variability.
Conclusions: With comprehensive care and inexpensive treatment, these patients can reach adulthood with acceptable quality of life, but unfortunately they are not treated properly. It would be advisable for each country to have primary and specialized care centers where patients can be cared for.


REFERENCES

  1. Natrajan K, Kutlar A. Disorders of hemoglobin structure: Sickle cell anemia and related abnormalities. In: Kaushansky K, Prchal JT, Press OW, Lichtman MA, M Levi, Burns LJ, et al. Williams Hematology. 9th ed. New York. McGraw-Hill Education; 2016. p. 762.

  2. Macharia AW, Mochamah G, Uyoga S, Ndila CM, Nyutu G, Makale J. The clinical epidemiology of sickle cell anemia in Africa. Am J Hematol. 2018 Mar;93(3):363-70. doi:10. 1002/ajh. 24986

  3. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong, Krishnamurti L et al. Sickle cell disease. Nat Rev Dis Primers. 2018Mar;4:18010. doi 10. 1038/nrdp. 2018

  4. Piel FB, Tatem AJ, Huang Z, Gupta S, Williams TN, Weatherall DJ. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health. 2014 Feb;2(2):e80-9.

  5. Elguero E, Délicat-Lombert LM, Rougeron V, Arnathau C, Roche B, Becquart P, et al. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci USA. 2015;112:7051-4.

  6. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017 Apr;376(16):1561-73.

  7. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008 Jun;86(6):480-7.

  8. Rajaratnam JK, Marcus JR, Flaxman AD, Wang H, Levin-Rector A, Dwyer L, et al. Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet. 2010 Jun;375(9730):1988-2008.

  9. Serjeant GR, Serjeant BE. Sickle cell disease. Oxford University Press. Lancet. 1997 Sep;350(9079):725-30.

  10. Wastnedge E, Waters D, Patel S, Morrison K, Goh MY, Adeloye D, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health. 2018 Dec;8(2):021103.

  11. Lindenau JD, Wagner SC, Castro SM, Hutz MH. The effects of old and recent migration waves in the distribution of HBB*S globin gene haplotypes. Genet Mol Biol. 2016 Oct-Dec;39(4):515-23.

  12. Weatherall D, Hofman K, Rodgers G, Ruffin J, Hrynkow S. A case for developing North-South partnerships for research in sickle cell disease. Blood. 2005 Feb;105(3):921-3.

  13. Livingstone FB. Aspects of the population dynamics of the abnormal haemoglobin and glucose-6-phosphate dehydrogenase deficiency genes. Am J Hum Genet. 1964 Dec;16:435-50.

  14. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec;376(9757):2018-31.

  15. Gardner K, Douiri A, Drasar E, Allman M, Mwirigi A, Awogbade M, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016 Sept;128(10):1436-8.

  16. Vichinsky E. Chronic organ failure in adult sickle cell disease. Hematology Am Soc Hematol Educ Program. 2017 Dec;(1):435-9. doi: 10. 1182/asheducation-2017. 1. 435.

  17. McGann PT. Time to invest in sickle cell anemia as a global health priority. Pediatrics. 2016 Jun;137(6): e20160348. doi: 10. 1542/peds. 2016-0348.

  18. Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries Br J Haematol. 2011 Sep;154(6):736-44.

  19. Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost effectiveness analysis. J Pediatr. 2000 Feb;136(2):201-8.

  20. Gravel S, Zakharia F, Moreno-Estrada A, Bymes JK, Muzzio M, Rodríguez-Flores JL et al. Reconstructing: Native American migrations from whole-genoma and whole exoma data. PLoS Genet. 2013;9(12):e1004023.

  21. Peñaloza-Espinosa RI, Buentello-Malo L, Hernández-Mayo MA, Nieva-García B, Lisker-Yurkowitzki R, Salamanca-Gómez F. Frecuencia de hemoglobina S en cinco poblaciones mexicanas y su importancia en salud pública. Salud pública Méx. 2008;50(4):325-29.

  22. Ruiz Reyes G. Hemoglobinas anormales en la República Mexicana. Rev Invest Clin. 1998;50(2):163-70.

  23. Ferguson D, Sanchez E, Rojo J. Prevalencia de hemoglobina AS en una población de adolescentes en Panamá. Rev Med Hosp Gen Mex. 2003;66:136-41.

  24. Rusanova I, Cossio G, Moreno B, Perea FJ, De Borace RG, Perea M et al. ß globin gene cluster haplotypes in sickle cell patients in Panama. Am J Hum Biol. 2011 May-Jun;23(3):377-80.

  25. Abarca G, Navarrete M, Trejos R, de Céspedes C, Saborío M. Abnormal hemoglobinopathies in the newborn human population of Costa Rica. Rev Biol Trop. 2008 Sep;56(3):995-1001

  26. Erazo BM, Ramírez GA, Cerrato LE, Pinto LJ, Castro EJ, Yanez NJ et al. Prevalence of HbS (HBB: C. 20 A>T) in a Honduran population of African descent. Hemoglobin2015;39(2):134-7.

  27. Garcia Jiménez OCTM, Bravo Urquiola M, Gómez Ortiz G, Montilla Fonseca S, Merzon R, de Donato M et al. Diagnosis of hemoglobinopathies in newborn in Venezuela hospitals. An Pediatr 2009;7(4):314-8

  28. Dominguez Y, Zurita C, Calvopiña D, Villaces J, Mora M. Prevalence of common hemoglobin variants in an afro-descendent Ecuadorian population. BMC Res Notes. 2013 Apr 4; 6:132. doi: 10. 1186/1756-0500-6-132.

  29. Echeverry-Coral SJ, Colmenares-Mejía CC, Yepes-Molina ZX, Martínez-Nieto O, Isaza-Ruget MA. Hemoglobinopathy detection through an institutional neonatal screening program in Colombia. J Bras Patol Med Lab. 2016 Oct; 52(5): 299-306.

  30. Alvear CB, Barboza M, Viola M, Moneriz C, Araque LM. Pilot study of hemoglobinopathies in newborns of the Rafael Calvo Maternity Clinic of Cartagena, Colombia. Colombia Med 2012;43(3):196-9.

  31. Lobo CL, Ballas SK, Domingos AC, Moura PG, do Nascimento EM, Cardoso GP, et al. Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil. Pediatr Blood Cancer. 2014 Jan;61(1):34-9.

  32. Fernández AP, Januario JN, Cangussu CB, Macedo DL, Viana MB. Mortality of children with sickle cell disease: a population study. J Pediatr (Rio J). 2010;86:279-84.

  33. Williams SA, Browne -Ferdinand B, Smart Y, Morella K, Reed SG, Kanter J. Newborn screening for sickle cell disease in ST. Vincent and the Granadines: Results of a pilot newborn screening program. Global Pediatr Health. 2017;4:1-7.

  34. Martínez G, Cañizares ME. Genetic hemoglobin abnormalities in 2363 Cuban newborns. Hum Genet. 1982;62(3):250-1

  35. Granda H, Gispert S, Dorticos A, Martín M, Cuadras Y, Calvo M et al. Cuban programme for prevention of sickle cell disease. Lancet. 1991 Jan 19;337(8734):152-3.

  36. Águila JD, Zamora MC, Fernández OA, Jiménez LP, Vicente OM, Alvarez IV. Comprehensive care for patients with sickle cell disease in Cuba. Haematologica. 2008 Jan;93(1):e20.

  37. Svarch E, Granda H, Martínez G, Espinosa E, Ferreira R. Programa nacional de prevención de la anemia drepanocítica. Plan piloto en el municipio 10 de Octubre. Rev Cub Pediatr 1984;56(3):59-74

  38. Serrano Mirabal J, García Peralta T, Svarch E, Menéndez Veitía A, Machín García S. Crecimiento prepuberal en la drepanocitosis. Rev Cub Hematol Inmunol Hemoter. 2016[acceso 10/12/2019];32(3):[aprox. 0 p. ]. Disponible en: Disponible en: http://www. revhematologia. sld. cu/index. php/hih/article/view/466

  39. Menendez Veitía A, Fernández Pla MA, Svarch Guerchicoff E, Scherle Matamoros C, Gil Agramonte M, Valdés Cabrera F, et al. Relación entre los factores de riesgo de accidente vascular encefálico en niños con drepanocitosis. Rev Cub Hematol, Inmunol Hemoter. 2017[acceso 30/11/2017];33(3):[aprox. 0 p. ]. Disponible en: Disponible en: http://www. revhematologia. sld. cu/index. php/hih/article/view/576

  40. Machín-García S, Svarch E. Drepanocitosis: 50 años de experiencia en cuba. Rev Cub de Hematol, Inmunol Hemoter. 2017 [citado 02/08/2018];33(S1):[aprox. 0 p. ]. Disponible en: Disponible en: http://www. revhematologia. sld. cu/index. php/hih/article/view/633

  41. Marcheco Teruel B, Suárez Besil B, Gómez Martínez M, Collazo Mesa T, Pérez Rodríguez J, García Heredia M, et al. Impacto del programa de prevención de anemia por hematíes falciformes en cuba: 1982-2016. Anales de la Academia de Ciencias de Cuba 2018;8(1):1-10

  42. Svarch E, Marcheco B, Machin S, Menéndez A, Nordet I, Arencibia A et al. La drepanocitosis en Cuba. Estudio en niños: Study in children. Rev Cub Hematol Inmunol Hemoter. 2011 Mar[acceso 24/03/2019];27(1). Disponible en: Disponible en: http://scielo. sld. cu/scielo. php?script=sci_arttext&pid=S0864-02892011000100005&lng=es

  43. Menéndez-Veitía A, Svarch E, Agramonte-Llanes O, Machín-García S, Gil-Agramonte M, Lam-Díaz R, et al. Propuesta para la implementación del registro nacional de la drepanocitosis. Rev Cub Hematol Inmunol Hemoter. 2017[acceso 02/05/2017];33(S1):[aprox. 0p. ]. Disponible en: Disponible en: http://www. revhematologia. sld. cu/index. php/hih/article/view/655

  44. Machín S, Álvarez I, Svarch E, Menéndez A, Hernández C, Sosa O. Morbilidad y mortalidad de la anemia drepanocítica. Estudio observacional de 36 años. Rev Cub Hematol Inmunol Hemoter. 2015[acceso 24/03/2019];31(3):[aprox. 0 p. ]. Disponible en: Disponible en: http://www. revhematologia. sld. cu/index. php/hih/article/view/268

  45. Project MA. Newborn estimates of Sickle-Cell disease table for World. 2010[accessed 19/05/2014]. Available from: Available from: http://www. map. ox. ac. uk/browse-resourcesSC/sickle-haemo-newborns-table/world/%3E

  46. UN. Annual number of births (BIRTHS). 2011 [accessed 19/05/2014]. Available from: Available from: http://data. Un. org/Data. aspx?d=SOWC&f=inID%3E

  47. Odame I. Developing global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin. Am J Prev Med. 2010 Apr;38(4 Suppl):S571-5.

  48. Villaescusa R. Carest (asociación caribeña para investigadores en drepanocitosis y talasemia): un logro caribeño que abre mayores oportunidades de cooperación. Rev Cub. Hematol Inmunol Hemoter. 2014[acceso 24/03/2019];30(2):[aprox. 0 p. ]. Disponible en: Disponible en: http://www. revhematologia. sld. cu/index. php/hih/article/view/171

  49. Knight-Madden J, Romana M, Villaescusa R, Reid M, Etienne-Julan M, Boutin L, et al. Carest- CAREST-Multilingual Regional Integration for Health Promotion and Research on Sickle Cell Disease and Thalassemia. Am J Public Health. 2016 May;106(5):851-3.

  50. Haywood C Jr, Lanzkron S, Hughes M, Brown R, Saha S, Beach MC. The association of clinician characteristics with their attitudes toward patients with sickle cell disease: Secondary analyses of a randomizes controlled trial. J Natl Med Assoc. 2015; jun;107(2):89-96.

  51. Lopez AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PGJ et al. Remembering the forgotten non-communicable diseases. BMC Med. 2014 Oct 22;12:200.

  52. Kyu HH, Pinho C, Wagner JA, Brown JC, Bertozzi-Villa A, Charlson FJ, et al. Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study. JAMA Pediatr. 2016 Mar;170(3):267-87.

  53. Chaturvedi S, DeBaun MR. Evolution of sickle cell disease from the life-threatening disease of children to a chronic disease of adults: The last 40 years. Am J Hematol. 2016 Jan;91(1):5-14.

  54. Giménez OG, Torrealba MC, Urquiola MB, Ortiz GG, Fonseca SM, Merzón R, et al. Diagnosis of hemoglobinopathies in newborns in Venezuela hospitals. An Pediatr (Barc). 2009 Oct;71(4):314-8




2020     |     www.medigraphic.com